Neuron-specific enolase in hypertension patients with acute ischemic stroke and its value forecasting long-term functional outcomes

Abstract

Background Neuron Specific Enolase (NSE), a neuro-biochemical protein marker, may correlate with the prognosis of stroke patients. Moreover, hypertension is the most common comorbidities in patients with acute ischemic stroke (AIS), and the relationship between NSE levels and long-term functional outcomes in such an increasingly large population is unclear. The aim of the study was to investigate the relationships mentioned above and optimize the prediction models. Methods From 2018 to 2020, 1086 admissions for AIS were grouped as hypertension and non-hypertension, while hypertension group was randomly divided into development and validation cohorts for internal validation. The severity of the stroke was staged by National Institutes of Health Stroke Scale (NIHSS) score. Stroke prognosis after 1 year of follow up was documented by modified Rankin Scale (mRS) score. Results Analysis revealed the following findings:(i) Serum NSE levels increased greatly in hypertension subjects with poor functional outcomes(p = 0.046). However, there was no association in non-hypertension individuals(p = 0.386). (ii) In addition to the conventional factors (age and NIHSS score), NSE (OR:1.241, 95% CI: 1.025–1.502) and prothrombin time were significantly related to the incidence of unfavorable outcomes. (iii)Based on the above four indicators, a novel nomogram was established to predict the prognosis of stoke in hypertension patients with the c-index values of 0.8851. Conclusions Overall, high baseline NSE is associated with poor 1-year AIS outcomes in hypertension patients, suggesting NSE may be a potential prognostic and therapeutic target for stroke in hypertension patients.

Comparative proteomic analysis of renal tissue of normotensive and hypertensive rats

“…For half of these proteins, good evidence exists in the literature for their association with hypertension and/or renal failure. These include phosphopyruvate hydratase [11], Ras-related protein Rab-11A [12], a kinesin-like protein [13], and biliverdin reductase A [14]. In the context of the development of hypertension, biliverdin reductase A (BVRA) is of particular interest.…”

Body fluids biomarkers associated with prognosis of acute ischemic stroke: progress and prospects

“…Wu et al found that plasma neurofilament light chain (pNfL) levels in ischemic stroke patients were significantly elevated at 2 days, 7 days and 6 months after stroke compared with healthy controls, and pNfL levels varied over time, suggesting that pNfL may be a promising biomarker for predicting severity in patients with acute neuroaxonal injury of AIS [ 92 ]. In addition, researchers found that serum neuron-specific enolase concentrations on the second day of admission predicted long-term functional outcomes at 1 year in patients with hypertensive AIS [ 93 ].…”

Electrical Activity Changes and Neurovascular Unit Markers in the Brains of Patients after Cardiac Surgery: Effects of Multi-Task Cognitive Training

“…Neuron-specific enolase (NSE) is a glycolytic enzyme that is produced in the cytoplasm of neurons and is precise enough in its ability to detect neuronal damage [27]. Neuronspecific enolase is increased in acute ischemic brain damage [28]. NSE is used as a marker for postoperative cerebral dysfunction in patients who have undergone coronary and carotid artery revascularization, but it is unclear whether it predicts cerebrovascular outcomes [29].…”